As an addendum to the above, I like to think that even if formalised DMOAD status proved elusive, and the agencies too non-commital on an achievable strategy.....all is not lost.
I, personal views only, think that a Zilosul approved as a pain/function therapeutic only will quickly gain an informal reputation amongst physicians and patients as a disease-modifying drug and will benefit from sales accordingly, in turn this will afford a lengthy runway for price increases over time.
We know what this drug does, and can do. Once it's on the market it will sell at profound scale.
- Forums
- ASX - By Stock
- PAR
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-67
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $89.31M |
Open | High | Low | Value | Volume |
28.0¢ | 29.0¢ | 25.0¢ | $737.9K | 2.729M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 152566 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.5¢ | 11596 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2600 | 0.250 |
7 | 93180 | 0.245 |
10 | 63700 | 0.240 |
7 | 105094 | 0.235 |
13 | 123914 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.255 | 18275 | 4 |
0.260 | 249833 | 6 |
0.265 | 63172 | 5 |
0.270 | 28674 | 4 |
0.285 | 83782 | 5 |
Last trade - 13.05pm 18/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |